| 23.01 0.02 (0.09%) | 03-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 27.1 | 1-year : | 31.66 |
| Resists | First : | 23.2 | Second : | 27.1 |
| Pivot price | 22.9  |
|||
| Supports | First : | 22.65 |
Second : | 22.3 |
| MAs | MA(5) : | 22.98 |
MA(20) : | 22.79 |
| MA(100) : | 14.9 |
MA(250) : | 10.1 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 76.6 |
D(3) : | 82.6 |
| RSI | RSI(14): 82.7 | |||
| 52-week | High : | 23.2 | Low : | 3.1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ HARP ] has closed below upper band by 33.2%. Bollinger Bands are 88.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 23.04 - 23.16 | 23.16 - 23.26 |
| Low: | 22.72 - 22.86 | 22.86 - 22.98 |
| Close: | 22.78 - 23.02 | 23.02 - 23.22 |
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Mon, 11 Mar 2024
Merck Completes Acquisition Of Harpoon Therapeutics - Quick Facts - Nasdaq
Mon, 08 Jan 2024
Merck Buys Harpoon Therapeutics To Expand Its Oncology Portfolio - Investopedia
Mon, 08 Jan 2024
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline - Business Wire
Mon, 23 Oct 2023
Harpoon climbs on data for cancer drug (NASDAQ:HARP) - Seeking Alpha
Fri, 15 Sep 2023
Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort - Yahoo Finance
Tue, 05 Sep 2023
Harpoon Therapeutics (NASDAQ: HARP) stock to rise 1,000% at the open - purely technical - Dhaka Tribune
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 21 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 82.8 (%) |
| Shares Short | 538 (K) |
| Shares Short P.Month | 548 (K) |
| EPS | -8.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.11 |
| Profit Margin | -81.7 % |
| Operating Margin | -273 % |
| Return on Assets (ttm) | -35.7 % |
| Return on Equity (ttm) | -284.4 % |
| Qtrly Rev. Growth | -67.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.74 |
| EBITDA (p.s.) | -1.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -69 (M) |
| Levered Free Cash Flow | -55 (M) |
| PE Ratio | -2.67 |
| PEG Ratio | 0 |
| Price to Book value | 20.72 |
| Price to Sales | 13.18 |
| Price to Cash Flow | -7.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|